Overall incidence of type I/II mutations at diagnosis or relapse
| Gene . | Diagnosis . | Relapse . | P . | ||
|---|---|---|---|---|---|
| No. of evaluated patients . | No. of patients with mutation (%) . | No. of evaluated patients . | No. of patients with mutation (%) . | ||
| FLT3/ITD | 67 | 14 (20.8) | 62 | 10 (16.1) | .14 |
| WT1 | 45 | 8 (17.8) | 42 | 14 (33.3) | .05 |
| RAS | 63 | 15 (23.8) | 52 | 10 (19.2) | .15 |
| NPM1 | 69 | 5 (7.2) | 68 | 4 (5.9) | .22 |
| CEBPα | 31 | 3 (9.6) | 30 | 4 (13.3) | .28 |
| KIT | 33 | 3 (9.1) | 27 | 2 (7.4) | ND |
| PTPN11 | 65 | 2 (3.5) | 58 | 0 (0.0) | ND |
| FLT3 D835 | 57 | 2 (3.5) | 50 | 1 (2.0) | ND |
| Gene . | Diagnosis . | Relapse . | P . | ||
|---|---|---|---|---|---|
| No. of evaluated patients . | No. of patients with mutation (%) . | No. of evaluated patients . | No. of patients with mutation (%) . | ||
| FLT3/ITD | 67 | 14 (20.8) | 62 | 10 (16.1) | .14 |
| WT1 | 45 | 8 (17.8) | 42 | 14 (33.3) | .05 |
| RAS | 63 | 15 (23.8) | 52 | 10 (19.2) | .15 |
| NPM1 | 69 | 5 (7.2) | 68 | 4 (5.9) | .22 |
| CEBPα | 31 | 3 (9.6) | 30 | 4 (13.3) | .28 |
| KIT | 33 | 3 (9.1) | 27 | 2 (7.4) | ND |
| PTPN11 | 65 | 2 (3.5) | 58 | 0 (0.0) | ND |
| FLT3 D835 | 57 | 2 (3.5) | 50 | 1 (2.0) | ND |
ND indicates not determined.